187949-86-6

Basic information

• Product Name: 3-amino-5-(4-chlorophenyl)-2-thiophenecarboxylic acid
• Synonyms: 3-amino-5-(4-chlorophenyl)-2-thiophenecarboxylic acid;3-Amino-5-(4-chlorophenyl)thiophene-2-carboxylic acid
• CAS NO: 187949-86-6
• Molecular Formula: C₁₁H₈ClNO₂S
• Molecular Weight: 253.7
• EINECS: 1312995-182-4
• Mol File: 187949-86-6.mol

Chemical Properties

• Boiling Point: 507.261 °C at 760 mmHg
• Flash Point: 260.582 °C
• Appearance: /
• Density: 1.483
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.689
• CAS DataBase Reference: 3-amino-5-(4-chlorophenyl)-2-thiophenecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-amino-5-(4-chlorophenyl)-2-thiophenecarboxylic acid(187949-86-6)
• EPA Substance Registry System: 3-amino-5-(4-chlorophenyl)-2-thiophenecarboxylic acid(187949-86-6)

Safety Data

• Hazardous Substances Data: 187949-86-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
Tiopronin is utilized as a pharmaceutical drug for the treatment of kidney stones, specifically targeting conditions that involve the formation of cystine stones. It functions by increasing the solubility of cystine in urine, which helps to prevent the crystallization process that leads to stone formation.
Used in the Treatment of Cystinuria:
In the medical field, tiopronin is applied as a therapeutic agent for cystinuria, a genetic disorder characterized by the excessive excretion of cystine in the urine. By enhancing cystine solubility, tiopronin mitigates the risk of cystine stone formation, thus managing the condition effectively.
Used in Renal Condition Management:
Tiopronin is also being explored for its potential in managing other renal conditions beyond kidney stones and cystinuria. Its ability to modulate the solubility of certain compounds in the urinary system positions it as a candidate for broader applications in renal health.
Used in Oral Administration:
Tiopronin is typically administered orally, making it a convenient and accessible treatment option for patients with kidney stone conditions. Its oral formulation allows for ease of use and patient compliance in managing their condition.

InChI:InChI=1/C11H8ClNO2S/c12-7-3-1-6(2-4-7)9-5-8(13)10(16-9)11(14)15/h1-5H,13H2,(H,14,15)

Upstream product

• 91076-93-6 methyl 3-amino-5-(4-chlorophenyl)-2-thiophenecarboxylate 
• 91076-94-7 5-(p-chlorophenyl)-3-amino-thiophene-2-carboxylic acid ethyl esther 
• 99-91-2 para-chloroacetophenone 
• 78583-86-5 (E)-3-Chloro-3-(4-chloro-phenyl)-acrylonitrile 

Downstream Products

• 1073282-34-4 4-(3-Amino-5-(4-chlorophenyl)thiophene-2-carboxamido)-2-methoxyphenyl acetate 
• 1073282-33-3 3-Amino-5-(4-chlorophenyl)-N-(4-(2-hydroxy-2-methylpropoxy)-3-methoxyphenyl)thiophene-2-carboxamide 
• 120428-62-8 5-(4-chlorophenyl)-3-thiopheneamine 
• 921592-80-5 3-amino-5-(4-chlorophenyl)-N-{4-[(3R)-3-hydroxypyrrolidin-1-yl]-3-methoxyphenyl}thiophene-2-carboxamide 
• 920976-06-3 3-amino-5-(4-chlorophenyl)-N-{4-[2-(3-hydroxypyrrolidin-1-yl)ethoxy]-3methoxyphenyl}thiophene-2-carboxamide 
• 649757-39-1 6-(4'-chlorophenyl)-2,4-dihydro-1H-thieno[3,2-d][1,3]oxazine-2,4-dione 
• 1585969-83-0 3-([1,1'-biphenyl]-4-ylcarboxamido)-5-(4-chlorophenyl)thiophene-2-carboxylic acid 
• 1585969-90-9 methyl 3-([1,1'-biphenyl]-4-ylcarboxamido)-5-(4-chlorophenyl)thiophene-2-carboxylate 
• 91076-93-6 methyl 3-amino-5-(4-chlorophenyl)-2-thiophenecarboxylate 
• 1428907-32-7 9-chloro-2-(4-chlorophenyl)-5,6,7,8-tetrahydrothieno[3,2-b]quinoline 

Relevant articles and documents

Novel small molecule inhibitors targeting the "switch region" of bacterial RNAP: Structure-based optimization of a virtual screening hit

Rising resistance against current antibiotics necessitates the development of antibacterial agents with alternative targets. The "switch region" of RNA polymerase (RNAP), addressed by the myxopyronins, could be such a novel target site. Based on a hit can

Synthesis of novel 2-thienylimino-1,3-thiazolidin-4-ones

The preparation of new 2-thienylimino-1,3-thiazolidin-4-ones from 3-aminothiophene-2-carboxylate using an easy four-step procedure is described. Georg Thieme Verlag Stuttgart New York.

THERAPEUTIC AGENTS

Compounds of formula (I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them.

THERAPEUTIC AGENTS

Compounds of formula (I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as deme

THERAPEUTIC AGENTS

Compounds of formula (I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as deme

SUBSTITUTED HETEROCYCLES AND THE USES THEREOF

This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.